STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated news page for Bristol-Myers Squibb Co. (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co..

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bristol-Myers Squibb Co.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bristol-Myers Squibb Co.'s position in the market.

News
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
Rhea-AI Summary
Bristol Myers Squibb and Cellares have entered into a $380M worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies. Cellares will provide its Cell Shuttle platform for Bristol Myers Squibb's clinical and commercial-scale manufacturing needs, enhancing agility, scalability, and turnaround time. This collaboration aims to bring the promise of cell therapies to more patients faster.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Building a Better Future: Bristol Myers Squibb 2023 ESG Report
Rhea-AI Summary
Bristol Myers Squibb (BMY) focuses on advancing patient health globally and enhancing ESG performance. The company aims to address health inequities, expand access to medicines in LMICs, and reduce environmental impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
-
News
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
Rhea-AI Summary
Bristol Myers Squibb presents promising data on KRAZATI (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer at AACR annual meeting. The study shows an objective response rate of 34%, with a median progression-free survival of 6.9 months and median overall survival of 15.9 months. Disease control was observed in 85% of patients, highlighting the potential of adagrasib for this specific patient group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
News
Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
Rhea-AI Summary
Bristol Myers Squibb (BMY) releases its 2023 Environmental, Social, and Governance (ESG) Report, highlighting progress in patient access, product innovation, and diversity. The company focuses on advancing patient health, scientific boundaries, and global workforce inclusivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
News
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Rhea-AI Summary
Bristol Myers Squibb (BMY) reports positive interim results from the Phase 3 EMERGENT-4 trial evaluating the long-term efficacy of KarXT in patients with schizophrenia. More than 75% of participants showed significant improvement in symptoms over 52 weeks, with promising safety and tolerability profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
Rhea-AI Summary
Bristol Myers Squibb presents favorable long-term metabolic profile and safety data for KarXT in schizophrenia treatment at the Annual Congress of the Schizophrenia International Research Society.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
Rhea-AI Summary
Abecma receives FDA approval for earlier use in treating relapsed or refractory multiple myeloma, demonstrating significant progression-free survival benefits and a well-established safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
fda approval
-
News
European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Rhea-AI Summary
Bristol Myers Squibb (BMY) receives expanded approval from the European Commission for Reblozyl (luspatercept) as a first-line treatment for adult patients with transfusion-dependent anemia due to myelodysplastic syndromes. The approval is based on the Phase 3 COMMANDS study, showing Reblozyl's superior efficacy over epoetin alfa in achieving transfusion independence and hemoglobin increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
-
News
Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
Rhea-AI Summary
Bristol Myers Squibb (BMY) releases its 2023 ESG Report focusing on patient access, innovation, and diversity. The report highlights the company's progress, strategy, and goals in ESG initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
News
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...
Rhea-AI Summary
Zai Lab and Bristol Myers Squibb announce positive results from the pivotal Phase 3 KRYSTAL-12 trial evaluating KRAZATI in KRASG12C-mutated NSCLC patients. Adagrasib shows significant benefits in progression-free survival and overall response rate compared to standard chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
clinical trial
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#118 Ranked by Market Cap
#4058 Ranked by Stock Gains
#659 Ranked by Dividends

BMY Stock Data

97.81B
2.02B
0.1%
78.93%
1.73%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.